Premium
5‐fluorouracil, etoposide, and cisplatin in the management of metastatic non‐small cell lung cancer
Author(s) -
Flaherty Lawrence,
Wozniak Antoinette,
Redman Bruce,
Kraut Michael,
Martino Silvana,
Heilbrun Lance,
Valdivieso Manuel
Publication year - 1991
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19910901)68:5<944::aid-cncr2820680506>3.0.co;2-g
Subject(s) - medicine , etoposide , cisplatin , fluorouracil , toxicity , lung cancer , chemotherapy , gastroenterology , performance status , oncology , cancer , surgery , urology
Encouraging response rates have been reported in Stage III non‐small cell lung cancer when 5‐fluorouracil (5‐FU), etoposide (VP‐16), and cisplatin (FED) have been combined with radiation therapy (RT) or RT and surgery. The current study evaluated the effectiveness of FED chemotherapy in 32 patients with metastatic non‐small cell lung cancer. Treatment consisted of 5‐FU (800 mg/m 2 /d) on days 1 to 4 by continuous infusion, intravenous (IV) VP‐16 (60 mg/m 2 ) over 1 hour on days 1 to 4, and IV cisplatin (60 mg/m 2 ) over 1 hour on day 1. Treatment cycles were repeated every 28 days as toxicity permitted. Partial responses occurred in 7 of 32 patients (22%; 95% confidence limit [CL] 0.09, 0.40), including 6 of 19 patients (32%) with performance status of 0 or 1, and 1 of 13 patients (8%) with performance status of 2 or 3. The median response duration was 5.0 months. Although toxicity was modest and consisted of primarily hematologic and gastrointestinal side effects, this combination does not appear to provide an advantage over other cisplatin combinations in Stage IV non‐small cell lung cancer.